$1 Billion is the total value of Vivo Capital, LLC's 49 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ARWR | Arrowhead Pharmaceuticals Inc | $42,728,000 | +47.7% | 2,328,475 | 0.0% | 4.26% | +15.4% | |
KALV | KalVista Pharmaceuticals Inc. | $38,899,000 | +44.9% | 1,359,149 | 0.0% | 3.88% | +13.2% | |
SVA | Sinovac Biotech Ltd. | $38,173,000 | -6.8% | 5,900,000 | 0.0% | 3.81% | -27.2% | |
FIXX | Homology Medicines, Inc. | $32,160,000 | +24.0% | 1,159,742 | 0.0% | 3.21% | -3.2% | |
MNLO | Menlo Therapeutics Inc. | $31,488,000 | +90.5% | 4,011,236 | 0.0% | 3.14% | +48.8% | |
TCDA | Tricida, Inc. | $29,529,000 | +60.4% | 781,185 | 0.0% | 2.94% | +25.2% | |
EIGR | Eiger BioPharmaceuticals Inc | $25,042,000 | +37.6% | 1,791,257 | 0.0% | 2.50% | +7.4% | |
MRTX | Mirati Therapeutics Inc. | $18,406,000 | +72.8% | 251,107 | 0.0% | 1.84% | +34.9% | |
MEIP | MEI Pharma Inc | $17,739,000 | +16.3% | 5,778,106 | 0.0% | 1.77% | -9.2% | |
IOVA | Iovance Biotherapeutics, Inc. | $15,216,000 | +7.5% | 1,600,000 | 0.0% | 1.52% | -16.1% | |
XENE | Xenon Pharmaceuticals Inc | $14,280,000 | +61.0% | 1,405,476 | 0.0% | 1.42% | +25.7% | |
ACER | Acer Therapeutics Inc | $14,071,000 | +20.8% | 579,051 | 0.0% | 1.40% | -5.7% | |
OBSV | Obseva SA | $11,986,000 | +1.0% | 937,147 | 0.0% | 1.20% | -21.1% | |
AMRS | Amyris, Inc | $11,653,000 | -37.4% | 5,575,785 | 0.0% | 1.16% | -51.1% | |
ZYME | Zymeworks Inc | $10,034,000 | +10.2% | 620,134 | 0.0% | 1.00% | -13.9% | |
ACRS | Aclaris Therapeutics, Inc. | $9,867,000 | -18.9% | 1,647,214 | 0.0% | 0.98% | -36.7% | |
VRNA | Verona Pharma PLCads | $9,704,000 | -27.8% | 1,492,951 | 0.0% | 0.97% | -43.6% | |
SLNO | Soleno Therapeutics, Inc. | $8,981,000 | +20.5% | 4,359,683 | 0.0% | 0.90% | -5.9% | |
KALA | Kala Pharmaceuticals, Inc. | $8,626,000 | +69.1% | 1,043,020 | 0.0% | 0.86% | +32.1% | |
GLMD | Galmed Pharmaceuticals Ltd | $7,936,000 | +19.6% | 971,337 | 0.0% | 0.79% | -6.6% | |
AUPH | Aurinia Pharmaceuticals Inc. | $7,886,000 | -4.7% | 1,213,290 | 0.0% | 0.79% | -25.6% | |
ZGNX | Zogenix Inc | $5,776,000 | +50.9% | 105,000 | 0.0% | 0.58% | +17.8% | |
SRRA | Sierra Oncology, Inc | $4,169,000 | +29.5% | 2,438,270 | 0.0% | 0.42% | +1.2% | |
AGRX | Agile Therapeutics, Inc. | $2,286,000 | +162.2% | 1,513,975 | 0.0% | 0.23% | +105.4% | |
DBVT | DBV Technologies S.A.adr | $2,082,000 | +20.1% | 269,995 | 0.0% | 0.21% | -5.9% | |
BPMX | BioPharmX Corporation | $1,419,000 | -18.4% | 16,128,515 | 0.0% | 0.14% | -36.5% | |
SELB | Selecta Biosciences Inc | $1,289,000 | -11.3% | 546,054 | 0.0% | 0.13% | -30.6% | |
AKTX | Akari Therapeutics Plcadr | $1,238,000 | +128.0% | 345,850 | 0.0% | 0.12% | +78.3% | |
SLNOW | Soleno Therapeutics, Inc. - Warrantwarrant | $28,000 | +47.4% | 188,772 | 0.0% | 0.00% | +50.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
CODEXIS INC | 29 | Q3 2023 | 8.0% |
ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
AMYRIS INC | 23 | Q3 2023 | 8.8% |
EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-04-22 |
13F-HR | 2024-02-07 |
13F-HR | 2023-11-08 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.